Table 1 Venture capital investments in companies targeting RNA modifications
From: RNA epigenetics spurs investor interest, but uncertainties linger
Company | Location | Amount raised | Group |
|---|---|---|---|
Storm TherapeuticsA round June 2017 | Cambridge | $21 million | Pfizer Ventures, M Ventures (a Merck KGaA subsidiary), Touchstone Innovations, Cambridge Innovation Capital, Taiho Ventures |
EPICS TherapeuticsSeed round May 2018 | Brussels | $9 million | Newton Capital Partners, S.R.I.W. Group, Theodorus |
Accent TherapeuticsA round May 2018 | Lexington, Massachusetts | $40 million | Atlas Venture, EcoR1 Capital, The Column Group |
Gotham TherapeuticsA round October 2018 | New York | $54 million | Versant Ventures, SR One, Forbion Capital Partners, Celgene, Alexandria Venture Investments |
Twentyeight-Seven TherapeuticsA round September 2018 | Cambridge, Massachusetts | $65 million | MPM Capital, Novartis Venture Fund, Johnson & Johnson Innovation, Vertex Ventures, Longwood Fund, Astellas Venture Management |
